{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:58:29Z","timestamp":1791428309284,"version":"4.3.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01052-7","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:51:04Z","timestamp":1746186664000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An Ocular Exposure Prediction for Topical Atropine in Human Using Physiologically Based Pharmacokinetic Modeling"],"prefix":"10.1208","volume":"27","author":[{"given":"Aole","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjiao","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Chi Lui","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4185-7732","authenticated-orcid":false,"given":"Taomin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"5","key":"1052_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036\u201342.","journal-title":"Ophthalmology"},{"issue":"3","key":"1052_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ophtha.2018.10.029","volume":"126","author":"KS Naidoo","year":"2019","unstructured":"Naidoo KS, Fricke TR, Frick KD, Jong M, Naduvilath TJ, Resnikoff S, et al. Potential Lost Productivity Resulting from the Global Burden of Myopia: Systematic Review, Meta-analysis, and Modeling. Ophthalmology. 2019;126(3):338\u201346.","journal-title":"Ophthalmology"},{"issue":"5","key":"1052_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ophtha.2018.01.033","volume":"125","author":"BS Modjtahedi","year":"2018","unstructured":"Modjtahedi BS, Ferris FL, Hunter DG, Fong DS. Public Health Burden and Potential Interventions for Myopia. Ophthalmology. 2018;125(5):628\u201330.","journal-title":"Ophthalmology"},{"issue":"4","key":"1052_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ophtha.2022.11.030","volume":"130","author":"RS Chong","year":"2023","unstructured":"Chong RS, Li H, Cheong AJY, Fan Q, Koh V, Raghavan L, et al. Mendelian Randomization Implicates Bidirectional Association between Myopia and Primary Open-Angle Glaucoma or Intraocular Pressure. Ophthalmology. 2023;130(4):394\u2013403.","journal-title":"Ophthalmology"},{"issue":"6","key":"1052_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1001\/jamaophthalmol.2020.1231","volume":"138","author":"X Han","year":"2020","unstructured":"Han X, Ong JS, An J, Craig JE, Gharahkhani P, Hewitt AW, et al. Association of Myopia and Intraocular Pressure With Retinal Detachment in European Descent Participants of the UK Biobank Cohort: A Mendelian Randomization Study. JAMA Ophthalmol. 2020;138(6):671\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"1052_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.preteyeres.2018.10.005","volume":"69","author":"J Ruiz-Medrano","year":"2019","unstructured":"Ruiz-Medrano J, Montero JA, Flores-Moreno I, Arias L, Garc\u00eda-Layana A, Ruiz-Moreno JM. Myopic maculopathy: Current status and proposal for a new classification and grading system (ATN). Prog Retin Eye Res. 2019;69:80\u2013115.","journal-title":"Prog Retin Eye Res"},{"issue":"8","key":"1052_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.ophtha.2018.01.035","volume":"125","author":"YN Yan","year":"2018","unstructured":"Yan YN, Wang YX, Yang Y, Xu L, Xu J, Wang Q, et al. Ten-Year Progression of Myopic Maculopathy: The Beijing Eye Study 2001\u20132011. Ophthalmology. 2018;125(8):1253\u201363.","journal-title":"Ophthalmology"},{"issue":"6","key":"1052_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","volume":"135","author":"Q Gong","year":"2017","unstructured":"Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624\u201330.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"1052_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","volume":"129","author":"A Ha","year":"2022","unstructured":"Ha A, Kim SJ, Shim SR, Kim YK, Jung JH. Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis. Ophthalmology. 2022;129(3):322\u201333.","journal-title":"Ophthalmology"},{"key":"1052_CR10","unstructured":"McLendon K, Preuss CV. Atropine. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Charles Preuss declares no relevant financial relationships with ineligible companies.: StatPearls Publishing. Copyright \u00a9 2023, StatPearls Publishing LLC.; 2023."},{"issue":"2","key":"1052_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/bja\/37.2.133","volume":"37","author":"KS Mehra","year":"1965","unstructured":"Mehra KS, Chandra P. THE EFFECT ON THE EYE OF PREMEDICATION WITH ATROPINE. Br J Anaesth. 1965;37(2):133\u20134.","journal-title":"Br J Anaesth"},{"key":"1052_CR12","doi-asserted-by":"crossref","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019;126(1):113\u201324.","DOI":"10.1016\/j.ophtha.2018.05.029"},{"key":"1052_CR13","doi-asserted-by":"crossref","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10(1):12750.","DOI":"10.1038\/s41598-020-69710-8"},{"issue":"3","key":"1052_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;65(3):315\u201325.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"1052_CR15","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.15761","volume":"102","author":"J Loughman","year":"2024","unstructured":"Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, et al. Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024;102(3):e245\u201356.","journal-title":"Acta Ophthalmol."},{"issue":"6","key":"1052_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.24162","volume":"329","author":"JC Yam","year":"2023","unstructured":"Yam JC, Zhang XJ, Zhang Y, Yip BHK, Tang F, Wong ES, et al. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA. 2023;329(6):472\u201381.","journal-title":"JAMA"},{"issue":"2","key":"1052_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0378-5173(89)90030-6","volume":"55","author":"D Meisner","year":"1989","unstructured":"Meisner D, Pringle J, Mezei M. Liposomal ophthalmic drug delivery. III. Pharmacodynamic and biodisposition studies of atropine. Int J Pharmaceutics. 1989;55(2):105\u201313.","journal-title":"Int J Pharmaceutics."},{"issue":"2","key":"1052_CR18","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1111\/aos.13889","volume":"97","author":"LZ Wang","year":"2019","unstructured":"Wang LZ, Syn N, Li S, Barathi VA, Tong L, Neo J, et al. The penetration and distribution of topical atropine in animal ocular tissues. Acta Ophthalmol. 2019;97(2):e238\u201347.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"1052_CR19","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s11095-021-03135-4","volume":"38","author":"M Ji","year":"2021","unstructured":"Ji M, Liu H, Ma S, Kong J, Jia Y, Gou J, et al. Stable Atropine Loaded Film As a Potential Ocular Delivery System For Treatment Of Myopia. Pharm Res. 2021;38(11):1931\u201346.","journal-title":"Pharm Res"},{"key":"1052_CR20","unstructured":"Center for Drug Evaluation, NMPA. Guideline for Clinical Trials of Locally Applied, Locally Acting Products. 2022. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=0696b4ad8d10ed92e6c68caa8098ea78. Accessed at Jan 2024."},{"issue":"7","key":"1052_CR21","first-page":"3473","volume":"61","author":"J Chowdhury","year":"2020","unstructured":"Chowdhury J, Balasubramanian M. A New Physiologically based Pharmacokinetic (PBPK)-Pharmacodynamic (PD) Model for Assessing Efficacy of Glaucoma Medication. Invest Ophthalmol Vis Sci. 2020;61(7):3473.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1052_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10928-023-09881-9","volume":"51","author":"S Naware","year":"2024","unstructured":"Naware S, Bussing D, Shah DK. Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2024;51(5):493\u2013508.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"1052_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/psp4.12918","volume":"12","author":"L Kuepfer","year":"2023","unstructured":"Kuepfer L, Fuellen G, Stahnke T. Quantitative systems pharmacology of the eye: Tools and data for ocular QSP. CPT Pharmacometrics Syst Pharmacol. 2023;12(3):288\u201399.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"1052_CR24","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.drudis.2019.05.039","volume":"24","author":"PJ Missel","year":"2019","unstructured":"Missel PJ, Sarangapani R. Physiologically based ocular pharmacokinetic modeling using computational methods. Drug Discov Today. 2019;24(8):1551\u201363.","journal-title":"Drug Discov Today"},{"issue":"4","key":"1052_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-019-0334-x","volume":"21","author":"M Le Merdy","year":"2019","unstructured":"Le Merdy M, Fan J, Bolger MB, Lukacova V, Spires J, Tsakalozou E, et al. Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension. Aaps j. 2019;21(4):65.","journal-title":"Aaps j"},{"key":"1052_CR26","unstructured":"Bolger MB, Spires J, Mullin JM, Macwan J, Ghosh J, Lukacova V, editors. Fluorometholone Ocular Suspension PBPK simulations using the OCAT\u2122 model in GastroPlus\u2122. GTCBio Ocular Disease Conference; 2012."},{"issue":"3","key":"1052_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00210-006-0054-5","volume":"373","author":"PK Harrison","year":"2006","unstructured":"Harrison PK, Tattersall JEH, Gosden E. The presence of atropinesterase activity in animal plasma. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(3):230\u20136.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"1052_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/j.1552-4604.1982.tb02638.x","volume":"22","author":"RG Adams","year":"1982","unstructured":"Adams RG, Verma P, Jackson AJ, Miller RL. Plasma Pharmacokinetics of Intravenously Administered Atropine in Normal Human Subjects. J Clin Pharmacol. 1982;22(10):477\u201381.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1052_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12917-021-02847-4","volume":"17","author":"L Strom","year":"2021","unstructured":"Strom L, Dalin F, Domberg M, Stenlund C, Bondesson U, Hedeland M, et al. Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility. BMC Vet Res. 2021;17(1):149.","journal-title":"BMC Vet Res"},{"issue":"10","key":"1052_CR30","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1023\/A:1026160023030","volume":"20","author":"F Huang","year":"2003","unstructured":"Huang F, Browne CE, Wu W-M, Juh\u00e1sz A, Ji F, Bodor N. Design, Pharmacokinetic, and Pharmacodynamic Evaluation of a New Class of Soft Anticholinergics. Pharm Res. 2003;20(10):1681\u20139.","journal-title":"Pharm Res"},{"issue":"9","key":"1052_CR31","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1517\/17425255.2014.934671","volume":"10","author":"Q Huang","year":"2014","unstructured":"Huang Q, Riviere JE. The application of allometric scaling principles to predict pharmacokinetic parameters across species. Expert Opin Drug Metab Toxicol. 2014;10(9):1241\u201353.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"1052_CR32","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1517\/17425255.2014.934671","volume":"10","author":"Q Huang","year":"2014","unstructured":"Huang Q, Riviere JE. The application of allometric scaling principles to predict pharmacokinetic parameters across species. Expert Opin Drug Metab Toxicol. 2014;10(9):1241\u201353.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1052_CR33","unstructured":"Drug Bank. https:\/\/go.drugbank.com\/drugs\/DB00572. Accessed at Mar 2023."},{"issue":"6","key":"1052_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/pharmaceutics12060554","volume":"12","author":"L Hellinen","year":"2020","unstructured":"Hellinen L, Bahrpeyma S, Rimpel\u00e4 A-K, Hagstr\u00f6m M, Reinisalo M, Urtti A. Microscale Thermophoresis as a Screening Tool to Predict Melanin Binding of Drugs. Pharmaceutics. 2020;12(6):554.","journal-title":"Pharmaceutics"},{"key":"1052_CR35","doi-asserted-by":"crossref","unstructured":"Mamada H, Iwamoto K, Nomura Y, Uesawa Y. Predicting blood-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans. Mol Divers. 2021;25(3):1261\u201370.","DOI":"10.1007\/s11030-021-10186-7"},{"key":"1052_CR36","doi-asserted-by":"crossref","unstructured":"Dehn WM. Comparative solubilities in water, in pyridine and in aqueous pyridine. J Am Chem Soc. 1917;39(7):1399\u2013404.","DOI":"10.1021\/ja02252a012"},{"issue":"2","key":"1052_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11095-022-03390-z","volume":"40","author":"M Le Merdy","year":"2023","unstructured":"Le Merdy M, AlQaraghuli F, Tan ML, Walenga R, Babiskin A, Zhao L, et al. Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation. Pharm Res. 2023;40(2):431\u201347.","journal-title":"Pharm Res"},{"issue":"12","key":"1052_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11095-020-02965-y","volume":"37","author":"M Le Merdy","year":"2020","unstructured":"Le Merdy M, Spires J, Lukacova V, Tan ML, Babiskin A, Xu X, et al. Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations. Pharm Res. 2020;37(12):245.","journal-title":"Pharm Res"},{"issue":"4","key":"1052_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0014-4835(80)90047-0","volume":"30","author":"B Atlasik","year":"1980","unstructured":"Atlasik B, Stepien K, Wilczok T. Interaction of drugs with ocular melanin in vitro. Exp Eye Res. 1980;30(4):325\u201331.","journal-title":"Exp Eye Res"},{"issue":"3","key":"1052_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/10517230050121615","volume":"10","author":"MR Easterling","year":"2000","unstructured":"Easterling MR, Evans MV, Kenyon EM. Comparative analysis of software for physiologically based pharmacokinetic modeling: simulation, optimization and sensitivity analysis. Toxicol Methods. 2000;10(3):203\u201329.","journal-title":"Toxicol Methods"},{"issue":"3","key":"1052_CR41","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","volume":"46","author":"A Upadhyay","year":"2020","unstructured":"Upadhyay A, Beuerman RW. Biological Mechanisms of Atropine Control of Myopia. Eye Contact Lens: Sci Clin Practice. 2020;46(3):129\u201335.","journal-title":"Eye Contact Lens: Sci Clin Practice"},{"issue":"22","key":"1052_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.9734\/jammr\/2022\/v34i2231593","volume":"34","author":"UA Eze","year":"2022","unstructured":"Eze UA, Nathaniel GI, Pepple GA. Ophthalmic Uses of Atropine: A Review. J Adv Med Med Res. 2022;34(22):197\u2013205.","journal-title":"J Adv Med Med Res"},{"key":"1052_CR43","doi-asserted-by":"crossref","unstructured":"Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, et al. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report. Ophthalmology. 2024.","DOI":"10.1016\/j.ophtha.2024.03.013"},{"issue":"8","key":"1052_CR44","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1001\/jamaophthalmol.2023.3076","volume":"141","author":"JJ Walline","year":"2023","unstructured":"Walline JJ, Berntsen DA. Atropine, 0.01%, for Myopia Control. JAMA Ophthalmol. 2023;141(8):766\u20137.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1052_CR45","doi-asserted-by":"publisher","first-page":"e0211376","DOI":"10.1371\/journal.pone.0211376","volume":"14","author":"N Mori","year":"2019","unstructured":"Mori N, Mochizuki T, Yamazaki F, Takei S, Mano H, Matsugi T, et al. MALDI imaging mass spectrometry revealed atropine distribution in the ocular tissues and its transit from anterior to posterior regions in the whole-eye of rabbit after topical administration. PLoS ONE. 2019;14(1):e0211376.","journal-title":"PLoS ONE"},{"issue":"7","key":"1052_CR46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/pharmaceutics16070914","volume":"16","author":"M Le Merdy","year":"2024","unstructured":"Le Merdy M, Spires J, Tan ML, Zhao L, Lukacova V. Clinical Ocular Exposure Extrapolation for a Complex Ophthalmic Suspension Using Physiologically Based Pharmacokinetic Modeling and Simulation. Pharmaceutics. 2024;16(7):914.","journal-title":"Pharmaceutics"},{"issue":"8","key":"1052_CR47","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","volume":"141","author":"MX Repka","year":"2023","unstructured":"Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141(8):756\u201365.","journal-title":"JAMA Ophthalmol."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01052-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01052-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01052-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:51:39Z","timestamp":1751622699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01052-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1052"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01052-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that they do not have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}},{"value":"Disclosure: A. Zheng, None; T. Han, None; F. Bu, None; Q. He, None; J. Shang, None; P. C. L. Ho, None; X. Xiang; X. Zhou, None; T. Huang, None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"89"}}